AMR/data-raw/breakpoints_eucast_raw.csv

"guideline","version","type","host","method","site","mo","rank_index","ab","ref_tbl","disk_dose","breakpoint_S","breakpoint_R","uti","is_SDD","is_screening","note","sheet"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [C] Susceptibility inferred from ampicillin.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [C] Susceptibility inferred from ampicillin.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","17",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] Breakpoints still under consideration.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] Breakpoints still under consideration.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam (uncomplicated UTI only)
E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone for E. coli.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam (uncomplicated UTI only)
E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone for E. coli.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales","10 mcg","22","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales",NA,"0.125","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen),Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B]  | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin","Enterobacterales","30 mcg","18","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin","Enterobacterales","10 mcg","17","14",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales","10 mcg","15","12",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin","Enterobacterales","10 mcg","17","14",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] Tigecycline has poor activity against Morganella morganii, Proteus spp. and Providencia spp. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method.","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] Tigecycline has poor activity against Morganella morganii, Proteus spp. and Providencia spp. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method.","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only)","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales","5 mcg","18","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","18","18",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","18","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","24","24",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin","Pseudomonas spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin","Pseudomonas spp.","30 mcg","18","15",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin","Pseudomonas spp.","10 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.","10 mcg","12","12",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin","Pseudomonas spp.","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"4","4",FALSE,FALSE,FALSE,"[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below).","S.maltophilia"
"EUCAST 2019","9.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,"[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below).","S.maltophilia"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin","Acinetobacter spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin","Acinetobacter spp.","30 mcg","19","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [E] For screening for methicillin resistance in S. pseudintermedius, see Note C on cephalosporins.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [E] For screening for methicillin resistance in S. pseudintermedius, see Note C on cephalosporins.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For dosing, see table of dosages.
2.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[2] For dosing, see table of dosages.
2.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. epidermidis","Staphylococcus spp.","30 mcg","25","25",FALSE,FALSE,FALSE,"[3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen), S. pseudintermedius","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] Cefoxitin screen for methicillin resistance in S. pseudintermedius is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm to screen for methicillin resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[6/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[6/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen)","Staphylococcus spp.","10 mcg","17","Note",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","18","16",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin,Coagulase-negative staphylococci","Staphylococcus spp.",NA,"8","16",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin,Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, 
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin, 
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","18","18",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Examine zone edges with transmitted light (plate held up to light).","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,"[A] Examine zone edges with transmitted light (plate held up to light).","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [B] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [B] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","23",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","21","18",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[B]  | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.","15 mcg","18","18",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2019","9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen)","Streptococcus groups A, B, C and G","10 mcg","12","Note",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","4",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","16",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae","2 mcg","22","16",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. For oxacillin non-susceptible isolates, always determine the MIC of benzylpenicillin.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.03","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen)","Streptococcus pneumoniae","10 mcg","10","Note",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","4",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","17",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen)","Viridans group streptococci","1 unit","18","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci","30 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Perform an MIC test.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Perform an MIC test.","Viridans group streptococci"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae","2 mcg","16","16",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/C] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae","10/10 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] For use in meningitis determine the meropenem MIC value.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] For use in meningitis determine the meropenem MIC value.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen)","Haemophilus influenzae","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.125","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen)","Moraxella catarrhalis","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","28","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2019","9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin","Neisseria meningitidis",NA,"0.06","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem(meningitis)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline","Neisseria meningitidis",NA,"1","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline","Neisseria meningitidis",NA,"1","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Benzylpenicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ampicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ampicillin-sulbactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Amoxicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Piperacillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Piperacillin-tazobactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ticarcillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Phenoxymethylpenicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Cefoxitin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ceftolozane-tazobactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ertapenem","Gram-positive anaerobes
except Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Imipenem","Gram-positive anaerobes
except Clostridioides difficile",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Meropenem","Gram-positive anaerobes
except Clostridioides difficile",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Meropenem-vaborbactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Moxifloxacin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Dalbavancin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Oritavancin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Teicoplanin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Telavancin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Vancomycin","Gram-positive anaerobes
except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Erythromycin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Clindamycin","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Doxycycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Eravacycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Minocycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Tetracycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Tigecycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Chloramphenicol","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Metronidazole","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile"
"EUCAST 2019","9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"C.difficile"
"EUCAST 2019","9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin","Gram-negative anaerobes",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem","Gram-negative anaerobes",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem","Gram-negative anaerobes",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem","Gram-negative anaerobes",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol","Gram-negative anaerobes",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2019","9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2019","9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen)","Pasteurella multocida","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2019","9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2019","9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2019","9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2019","9.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2019","9.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","17",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone. for E. coli","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone. for E. coli","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","Enterobacterales","10 mcg","22","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganella morganii,Proteus spp. and Providencia spp.","Enterobacterales","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganella spp.","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganella spp.","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B]  | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only)","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","24","24",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2020","10.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi, see Note C on cephalosporins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi, see Note C on cephalosporins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.","30 mcg","25","25",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius and S. schleiferi","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] Cefoxitin screen for methicillin resistance in S. pseudintermediusand S. schleiferi is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm to screen for methicillin resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (indications other than pneumonia)","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline, S. aureus (pneumonia)","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[7/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[7/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.
C.Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.
C.Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","Note",FALSE,FALSE,FALSE,"[C] ","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","20",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The zone diameter breakpoint is valid for MSSA only. For MRSA, perform an MIC test.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] The zone diameter breakpoint is valid for MSSA only. For MRSA, perform an MIC test.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","23",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.1.E. faecium resistant to penicillins can be considered resistant to all other beta-lactam agents including carbapenems.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[B]  | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2020","10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","Note",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","Streptococcus pneumoniae","2 mcg","22","16",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5/B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For use in meningitis determine the meropenem MIC.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For use in meningitis determine the meropenem MIC.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","Note",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","17",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","18","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci","30 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae","10/10 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","IP mcg","IP","IP",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","28","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Breakpoints relate to topical use only.","M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2020","10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin","Neisseria meningitidis",NA,"0.06","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Benzylpenicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ampicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ampicillin-sulbactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Amoxicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Piperacillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Piperacillin-tazobactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ticarcillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Phenoxymethylpenicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Cefoxitin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ceftolozane-tazobactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ertapenem","Gram-positive anaerobes
except Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Imipenem","Gram-positive anaerobes
except Clostridioides difficile",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Imipenem-relebactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Meropenem","Gram-positive anaerobes
except Clostridioides difficile",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Meropenem-vaborbactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Moxifloxacin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Dalbavancin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Oritavancin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Teicoplanin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Telavancin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Vancomycin","Gram-positive anaerobes
except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Erythromycin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Clindamycin","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Doxycycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Eravacycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Minocycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Tetracycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Tigecycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Chloramphenicol","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Metronidazole","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile"
"EUCAST 2020","10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"C.difficile"
"EUCAST 2020","10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin","Gram-negative anaerobes",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem","Gram-negative anaerobes",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem","Gram-negative anaerobes",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam","Gram-negative anaerobes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem","Gram-negative anaerobes",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol","Gram-negative anaerobes",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2020","10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2020","10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","Pasteurella multocida","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2020","10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2020","10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2020","10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei"
"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei"
"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","50","23",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei"
"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2020","10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2020","10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2020","10.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2020","10.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti,M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","25","25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","20","20",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","30","30",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2020","10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[C] Breakpoints still under consideration. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[C] Breakpoints still under consideration. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[5/C] Breakpoints still under consideration.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam, Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B]  | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)","Pseudomonas spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.","IP mcg","IP","IP",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2021","11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2021","11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2021","11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin,S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), 
S. pseudintermedius and S. schleiferi","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis","Staphylococcus spp.","30 mcg","25","25",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), 
S. pseudintermedius and S. schleiferi","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), 
S. pseudintermedius and S. schleiferi","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline(indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline(indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","Note",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","23",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis),  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis),  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","Note",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","16",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[E] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC for meropenem.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC for meropenem.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","Note",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","17",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","18","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam,S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam,S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae","10/10 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","28","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2021","11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Benzylpenicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ampicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ampicillin-sulbactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Amoxicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Piperacillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Piperacillin-tazobactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ticarcillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Phenoxymethylpenicillin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Cefiderocol","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Cefoxitin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ceftolozane-tazobactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Doripenem","Gram-positive anaerobes
except Clostridioides difficile",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Ertapenem","Gram-positive anaerobes
except Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Imipenem","Gram-positive anaerobes
except Clostridioides difficile",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Imipenem-relebactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Meropenem","Gram-positive anaerobes
except Clostridioides difficile",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Meropenem-vaborbactam","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Moxifloxacin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Dalbavancin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Oritavancin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Teicoplanin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Telavancin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Vancomycin","Gram-positive anaerobes
except Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Erythromycin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Clindamycin","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Doxycycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Eravacycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Minocycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Tetracycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Tigecycline","Gram-positive anaerobes
except Clostridioides difficile",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Chloramphenicol","Gram-positive anaerobes
except Clostridioides difficile",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Lefamulin","Gram-positive anaerobes
except Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Gram-positive anaerobes
except Clostridioides difficile",NA,"Metronidazole","Gram-positive anaerobes
except Clostridioides difficile",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile"
"EUCAST 2021","11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"C.difficile"
"EUCAST 2021","11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.difficile"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin","Gram-negative anaerobes",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin","Gram-negative anaerobes",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid","Gram-negative anaerobes",NA,"4","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin","Gram-negative anaerobes",NA,"16","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid","Gram-negative anaerobes",NA,"8","16",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doripenem","Gram-negative anaerobes",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem","Gram-negative anaerobes",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem","Gram-negative anaerobes",NA,"2","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam","Gram-negative anaerobes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem","Gram-negative anaerobes",NA,"2","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline","Gram-negative anaerobes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline","Gram-negative anaerobes",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol","Gram-negative anaerobes",NA,"8","8",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole","Gram-negative anaerobes",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobes, Gramnegative"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","Pasteurella multocida","30 mcg","23","Note",FALSE,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2021","11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2021","11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2021","11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2021","11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2021","11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2021","11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2021","11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2021","11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2021","11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp.
except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as susceptible to norfloxacin can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as resistant to norfloxacin can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2021","11.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei"
"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei"
"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","50","23",FALSE,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei"
"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2021","11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2021","11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2021","11.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2021","11.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2021","11.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","20","20",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2021","11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","Enterobacterales","75 mcg","23","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp. Klebsiella spp., 
Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp. Klebsiella spp., 
Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination. | [C] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)Salmonella spp.","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[B]  | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion screening test. | [C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales","30 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","Pseudomonas spp.","75 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2022","12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2022","12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2022","12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudinter-medius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S.lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S.lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), 
S. pseudintermedius, S. schleiferi and
S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), 
S. pseudintermedius, S. schleiferi and
S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","19",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis),  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis),  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","18",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","17",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","20",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"8","8",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","Note",FALSE,FALSE,FALSE,"[D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","19",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"8","8",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae","30 mcg","21","21",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","18","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","18","18",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2022","12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (prophylaxis only)","Neisseria meningitidis",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, 
B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, 
B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2022","12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","Pasteurella multocida","1 unit","17","17",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","Pasteurella multocida","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","Pasteurella multocida","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","Pasteurella multocida","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","Pasteurella multocida","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","P.multocida"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline","Pasteurella multocida",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","Pasteurella multocida","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida"
"EUCAST 2022","12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2022","12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","Pasteurella multocida","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"P.multocida"
"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","Campylobacter jejuni and coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline","Campylobacter jejuni and coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","Campylobacter jejuni and coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","Corynebacterium spp.","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","Corynebacterium spp.","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","Corynebacterium spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","Corynebacterium spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","Corynebacterium spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","Corynebacterium spp.","15 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","Corynebacterium spp.","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","Corynebacterium spp.","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","Corynebacterium spp.","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.",NA,"0.06","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","Corynebacterium spp.","5 mcg","30","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","Aerococcus sanguinicola and urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","Aerococcus sanguinicola and urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","Aerococcus sanguinicola and urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","Aerococcus sanguinicola and urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2022","12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2022","12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2022","12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2022","12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2022","12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2022","12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2022","12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2022","12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","18","18",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp.
except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2022","12.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2022","12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2022","12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2022","12.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2022","12.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2022","12.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2022","12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and 
P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents.The ECOFF is 256 mg/L.","Pseudomonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2023","13.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2023","13.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2023","13.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), 
S. pseudintermedius, S. schleiferi and
S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), 
S. pseudintermedius, S. schleiferi and
S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis),  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis),  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"8","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, 
B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, 
B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,"[2/A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[3/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2023","13.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2023","13.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2023","13.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2023","13.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2023","13.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2023","13.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp.
except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2023","13.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2023","13.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2023","13.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2023","13.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","22","22",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","Enterobacterales","200 mcg","21","21",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents.The ECOFF is 256 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2023","13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2023","13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2023","13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.","10/25 mcg","24","24",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), 
S. pseudintermedius, S. schleiferi and
S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), 
S. pseudintermedius, S. schleiferi and
S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","21",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"32","32",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis),  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis),  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","Streptococcus groups A, B, C and G","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","5 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","Streptococcus pneumoniae","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2023","13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, 
B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam, 
B. thetaiotaomicron","Bacteroides spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IE","IE",FALSE,FALSE,FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2023","13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2023","13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","29","29",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2023","13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2023","13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2023","13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2023","13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp.
except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2023","13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2023","13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2023","13.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2023","13.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2023","13.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2023","13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","25","25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2024","14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2024","14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2024","14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/. | [A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[6/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[8/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","17",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[D]  | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","Enterococcus spp.","2 mcg","10","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"4","8",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [B] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[1/A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [B] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecalis","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline, E. faecium","Enterococcus spp.","20 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecalis","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis),  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (meningitis),  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.06","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4/B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci",NA,"0.25","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3/B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors. | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors. | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[4/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2024","14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2024","14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2024","14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2024","14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2024","14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2024","14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2024","14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2024","14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp.
except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis","1 unit","50","18",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis",NA,"0.001","0.25",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis","5 mcg","10","10",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis","30 mcg","26","26",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2024","14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis","5 mcg","12","12",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis","30 mcg","30","30",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis","5 mcg","50","27",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis","5 mcg","50","28",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis","10 mcg","23","23",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis","10 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis","30 mcg","42","42",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis "
"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis","5 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis "
"EUCAST 2024","14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis "
"EUCAST 2024","14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis "
"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2024","14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2024","14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2024","14.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2024","14.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2024","14.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents","5 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","Topical agents","30 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","24","24",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.
ND = No ECOFF available.","Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.
ND = No ECOFF available.","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents","200 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents",NA,"ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2024","14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","ND","ND",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales","30/20 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","27","27",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales","30/20 mcg","25","25",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), 
E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), 
E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim 
(uncomplicated UTI only)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","Enterobacterales","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","S.maltophilia"
"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","S.maltophilia"
"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.maltophilia"
"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.maltophilia"
"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2025","15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant.","Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant.","Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","14","11",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","17",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[D]  | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","17","14",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.","2 mcg","10","10",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,TRUE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G","1 unit","23","23",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin,  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin,  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"1","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","1",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","1 unit","Note","Note",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","13","10",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.25","1",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci",NA,"21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci",NA,"1","1",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci",NA,"12","12",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci","2 mcg","21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","32","32",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[B]  | [B] Susceptibility can be inferred from the nalidixic acid screening test. | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","20",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","18","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","Fusobacterium necrophorum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","Fusobacterium necrophorum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin","Fusobacterium necrophorum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","Fusobacterium necrophorum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","Fusobacterium necrophorum","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","Fusobacterium necrophorum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","Fusobacterium necrophorum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","Fusobacterium necrophorum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","Fusobacterium necrophorum","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2025","15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2025","15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2025","15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae","2/1 mcg","22","22",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"2","4",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2025","15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","19","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","A.xylosoxidans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant.","A.xylosoxidans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2025","15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2025","15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2025","15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp.
except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis","1 unit","50","18",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis",NA,"0.001","0.25",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis","5 mcg","10","10",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis","30 mcg","26","26",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2025","15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis","5 mcg","12","12",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis","30 mcg","30","30",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis","5 mcg","50","27",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis","5 mcg","50","28",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis","10 mcg","23","23",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis","10 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis","30 mcg","42","42",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis "
"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis","5 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis "
"EUCAST 2025","15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis "
"EUCAST 2025","15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis "
"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2025","15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2025","15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2025","15.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2025","15.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2025","15.0","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.
ND = No ECOFF available.","Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.
ND = No ECOFF available.","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2025","15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","Enterobacterales","10 mcg","14","14",FALSE,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","Enterobacterales","10/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"".","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral).","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","Enterobacterales","/ mcg","Note","Note",FALSE,FALSE,FALSE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","Enterobacterales","20/10 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales",NA,"32","32",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterobacterales","20/10 mcg","16","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales",NA,"0.001","8",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","Enterobacterales","20/10 mcg","50","19",FALSE,FALSE,TRUE,"[3/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","Enterobacterales","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","Enterobacterales","30/6 mcg","20","20",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales",NA,"8","16",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","Enterobacterales","75/10 mcg","23","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales",NA,"0.001","16",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin (infections originating from the urinary tract), E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis","Enterobacterales","30 mcg","50","17",FALSE,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only),E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis","Enterobacterales","10 mcg","15","15",FALSE,FALSE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination. | [F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","Enterobacterales","30 mcg","12","12",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","Enterobacterales","30 mcg","14","14",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefazolin (infections originating from the urinary tract), E. coli and Klebsiella spp.(except K. aerogenes)","Enterobacterales","30 mcg","50","20",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","Enterobacterales","30/20 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","Enterobacterales","5 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","Enterobacterales","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","Enterobacterales","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime 
(uncomplicated UTI only)","Enterobacterales","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","Enterobacterales","10/4 mcg","13","13",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","Enterobacterales","30 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","Enterobacterales","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","Enterobacterales","30/10 mcg","22","22",FALSE,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","Enterobacterales","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","Enterobacterales","30 mcg","27","27",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis","Enterobacterales","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales",NA,"1","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","Enterobacterales","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","Enterobacterales","10 mcg","23","23",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Enterobacterales except Morganellaceae","Enterobacterales","10 mcg","22","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem, Morganellaceae","Enterobacterales","10 mcg","50","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem-relebactam,Enterobacterales except Morganellaceae","Enterobacterales","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales",NA,"2","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","Enterobacterales","10 mcg","22","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","Enterobacterales","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","Enterobacterales","20/10 mcg","20","20",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales",NA,"1","4",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","Enterobacterales","30 mcg","26","21",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales",NA,"4","4",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","Enterobacterales","30/20 mcg","25","25",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin, Salmonella spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","Enterobacterales","5 mcg","25","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","Enterobacterales","5 mcg","24","24",FALSE,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Delafloxacin, E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","Enterobacterales","5 mcg","23","19",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin, Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.","Enterobacterales","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","Enterobacterales","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","Enterobacterales","5 mcg","24","22",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","Enterobacterales","30 mcg","18","18",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","Enterobacterales","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","Enterobacterales",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","Enterobacterales","10 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Eravacycline, E. coli","Enterobacterales","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tigecycline,E. coli and C. koseri","Enterobacterales","15 mcg","18","18",FALSE,FALSE,FALSE,"[3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"2","2",FALSE,FALSE,TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Use an MIC method (broth microdilution only).","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (infections originating from the urinary tract), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv (other indications), E. coli","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv,other Enterobacterales","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral 
(uncomplicated UTI only), E. coli","Enterobacterales","200 mcg","24","24",FALSE,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gepotidacin (uncomplicated UTI only),E. coli","Enterobacterales",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gepotidacin (uncomplicated UTI only),E. coli","Enterobacterales",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitrofurantoin (uncomplicated UTI only), E. coli","Enterobacterales","100 mcg","11","11",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales",NA,"16","16",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Nitroxoline (uncomplicated UTI only), 
E. coli","Enterobacterales","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), E. coli and Klebsiella spp. (except K. aerogenes)","Enterobacterales","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), Proteus spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[7/G] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only), Proteus spp.","Enterobacterales",NA,"Note","Note",FALSE,FALSE,FALSE,"[7/G] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, 
Enterobacterales except Serratia spp.","Enterobacterales",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, 
Enterobacterales except Serratia spp.","Enterobacterales","1.25/23.75 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, 
Serratia spp.","Enterobacterales",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole, 
Serratia spp.","Enterobacterales","1.25/23.75 mcg","50","15",FALSE,FALSE,FALSE,NA,"Enterobacterales"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","Pseudomonas spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","Pseudomonas spp.","75/10 mcg","50","18",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","Pseudomonas spp.","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefiderocol, P. aeruginosa","Pseudomonas spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","Pseudomonas spp.","10 mcg","50","17",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime-avibactam, P. aeruginosa","Pseudomonas spp.","10/4 mcg","17","17",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftolozane-tazobactam, P. aeruginosa","Pseudomonas spp.","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","Pseudomonas spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","Pseudomonas spp.","10 mcg","50","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem-relebactam, P. aeruginosa","Pseudomonas spp.","10/25 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","14",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than 
P. aeruginosa","Pseudomonas spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem(indications other than meningitis),Pseudomonas other than 
P. aeruginosa","Pseudomonas spp.","10 mcg","24","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis), P. aeruginosa","Pseudomonas spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.",NA,"8","8",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem-vaborbactam, 
P. aeruginosa","Pseudomonas spp.","20/10 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","Pseudomonas spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","Pseudomonas spp.","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","Pseudomonas spp.","5 mcg","50","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"16","16",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","Pseudomonas spp.","30 mcg","15","15",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","Pseudomonas spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","Pseudomonas spp.","10 mcg","18","18",FALSE,FALSE,FALSE,NA,"Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"4","4",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv","Pseudomonas spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","S.maltophilia"
"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","Stenotrophomonas maltophilia","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","S.maltophilia"
"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1/A] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia"
"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam","Stenotrophomonas maltophilia",NA,"IE","IE",FALSE,FALSE,FALSE,"[1/A] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia"
"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline","Stenotrophomonas maltophilia",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2026","16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","Stenotrophomonas maltophilia","1.25/23.75 mcg","50","16",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","S.maltophilia"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","Acinetobacter spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.",NA,"0.001","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","Acinetobacter spp.","10 mcg","50","22",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.",NA,"2","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","Acinetobacter spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.",NA,"2","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","Acinetobacter spp.","10 mcg","21","15",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","Acinetobacter spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","Acinetobacter spp.","5 mcg","50","21",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","Acinetobacter spp.","5 mcg","23","20",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","Acinetobacter spp.","30 mcg","19","19",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","Acinetobacter spp.","10 mcg","17","17",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline","Acinetobacter spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"2","2",FALSE,FALSE,TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method (broth microdilution only).","Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv","Acinetobacter spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","Acinetobacter spp.","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,NA,"Acinetobacter"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. aureus","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, S. lugdunensis","Staphylococcus spp.","1 unit","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Benzylpenicillin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin,S. saprophyticus","Staphylococcus spp.","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Phenoxymethylpenicillin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.","1 mcg","20","20",FALSE,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oxacillin,other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2/C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except 
S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci except 
S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. epidermidis and S. lugdunensis","Staphylococcus spp.","30 mcg","27","27",FALSE,FALSE,FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefoxitin (screen only), S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[6/C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.",NA,"1","2",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (indications other than pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","17",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftaroline (pneumonia), S. aureus","Staphylococcus spp.","5 mcg","20","20",FALSE,FALSE,FALSE,"[7/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftobiprole, S. aureus","Staphylococcus spp.","5 mcg","17","17",FALSE,FALSE,FALSE,"[9/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","17",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","2",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ciprofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,TRUE,"[2/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"0.016","0.016",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (community-acquired pneumonia), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Delafloxacin (skin and skin structure infections), S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, S. aureus","Staphylococcus spp.","5 mcg","50","22",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.001","1",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Levofloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","50","24",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, S. aureus","Staphylococcus spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Moxifloxacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","28","28",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","Staphylococcus spp.","10 mcg","17","17",FALSE,FALSE,FALSE,"[D]  | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, S. aureus","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"16","16",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amikacin, 
Coagulase-negative staphylococci","Staphylococcus spp.","30 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gentamicin,
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","22","22",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, S. aureus","Staphylococcus spp.","10 mcg","18","18",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tobramycin, 
Coagulase-negative staphylococci","Staphylococcus spp.","10 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Oritavancin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin,S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Teicoplanin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telavancin,MRSA","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Vancomycin, 
Coagulase-negative staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","Staphylococcus spp.","2 mcg","22","22",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","Staphylococcus spp.","15 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Eravacycline, S. aureus","Staphylococcus spp.","20 mcg","20","20",FALSE,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","Staphylococcus spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","Staphylococcus spp.","30 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","Staphylococcus spp.","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","Staphylococcus spp.","10 mcg","21","21",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","Staphylococcus spp.","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin, S. aureus","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin, S. aureus","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For other staphylococci, the ECOFF can be used to exclude acquired resistance mechanisms, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin, other staphylococci","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] For other staphylococci, the ECOFF can be used to exclude acquired resistance mechanisms, see https://www.eucast.org/eucastguidancedocuments/. | [A] Use an MIC method.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv","Staphylococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","Staphylococcus spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Lefamulin, S. aureus","Staphylococcus spp.","5 mcg","23","23",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only),S. saprophyticus","Staphylococcus spp.","100 mcg","13","13",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Nitroxoline (uncomplicated UTI only), 
S. saprophyticus","Staphylococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, S. aureus","Staphylococcus spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin, Coagulase-negative staphylococci","Staphylococcus spp.","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Staphylococcus spp.","5 mcg","19","19",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Staphylococcus spp.","1.25/23.75 mcg","24","24",FALSE,FALSE,FALSE,NA,"Staphylococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","Enterococcus spp.","2 mcg","10","10",FALSE,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,TRUE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (other indications),E. faecalis","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4/D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin, E. faecalis","Enterococcus spp.","30 mcg","50","18",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.",NA,"0.001","16",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam, E. faecalis","Enterococcus spp.","30/6 mcg","50","18",FALSE,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem, E. faecalis","Enterococcus spp.","10 mcg","50","21",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","Enterococcus spp.","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","Enterococcus spp.","300 mcg","Note","Note",FALSE,FALSE,FALSE,"[3/B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.",NA,"2","2",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","Enterococcus spp.","30 mcg","16","16",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, E. faecalis and E. faecium","Enterococcus spp.","5 mcg","12","12",FALSE,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, other enterococci","Enterococcus spp.","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Quinupristin-dalfopristin, E. faecium","Enterococcus spp.","15 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","Enterococcus spp.","20 mcg","22","22",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","Enterococcus spp.","15 mcg","20","20",FALSE,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.",NA,"4","4",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","Enterococcus spp.","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),E. faecalis","Enterococcus spp.",NA,"8","8",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gepotidacin (uncomplicated UTI only),E. faecalis","Enterococcus spp.",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), 
E. faecalis","Enterococcus spp.",NA,"64","64",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitrofurantoin (uncomplicated UTI only), 
E. faecalis","Enterococcus spp.","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)","Enterococcus spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","Enterococcus spp.","5 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","Enterococcus spp.","1.25/23.75 mcg","Note","Note",FALSE,FALSE,FALSE,"[4/C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin, Streptococcus groups A, C and G","Streptococcus groups A, B, C and G","1 unit","23","23",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin,  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin,  S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","1 unit","18","18",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Phenoxymethylpenicillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dicloxacillin
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Flucloxacillin 
Streptococcus groups A, C and G","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G",NA,"0.001","2",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","Streptococcus groups A, B, C and G","5 mcg","50","17",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","Streptococcus groups A, B, C and G","5 mcg","19","19",FALSE,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","Streptococcus groups A, B, C and G","10 mcg","12","12",FALSE,FALSE,FALSE,"[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","Streptococcus groups A, B, C and G","30 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","Streptococcus groups A, B, C and G","5 mcg","13","13",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","Streptococcus groups A, B, C and G","15 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","Streptococcus groups A, B, C and G","2 mcg","17","17",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","Streptococcus groups A, B, C and G","30 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","Streptococcus groups A, B, C and G","15 mcg","19","19",FALSE,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G",NA,"2","2",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","Streptococcus groups A, B, C and G","10 mcg","19","19",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","Streptococcus groups A, B, C and G","2 mcg","18","18",FALSE,FALSE,FALSE,"[2/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"1","1",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin","Streptococcus groups A, B, C and G",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"64","64",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Nitrofurantoin (uncomplicated UTI only), 
S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G","100 mcg","15","15",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","Streptococcus groups A, B, C and G","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci)","Streptococcus groups A, B, C and G",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","Streptococcus groups A, B, C and G","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","1",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","1 unit","Note","Note",FALSE,FALSE,FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae","2 mcg","22","19",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3/C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","Streptococcus pneumoniae","1 mcg","20","20",FALSE,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","Streptococcus pneumoniae","30 mcg","50","28",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefadroxil","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefadroxil","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefalexin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefalexin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefazolin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefazolin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"0.5","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","Streptococcus pneumoniae","5 mcg","50","16",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","Streptococcus pneumoniae","10 mcg","10","10",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","Streptococcus pneumoniae","30 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","Streptococcus pneumoniae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","Streptococcus pneumoniae","15 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","Streptococcus pneumoniae","2 mcg","19","19",FALSE,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","Streptococcus pneumoniae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","Streptococcus pneumoniae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae",NA,"2","2",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","Streptococcus pneumoniae","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","Streptococcus pneumoniae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv","Streptococcus pneumoniae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","Streptococcus pneumoniae","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","Streptococcus pneumoniae","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae",NA,"1","1",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","Streptococcus pneumoniae","1.25/23.75 mcg","15","15",FALSE,FALSE,FALSE,NA,"S.pneumoniae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.25","1",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","Viridans group streptococci","1 unit","21","12",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","Viridans group streptococci","1 unit","21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci",NA,"1","1",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","Viridans group streptococci","1 unit","12","12",FALSE,FALSE,TRUE,"[2/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","Viridans group streptococci","2 mcg","21","15",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","Viridans group streptococci","2 mcg","21","21",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"0.5","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4/C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","Viridans group streptococci","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","Viridans group streptococci","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftolozane-tazobactam, S. anginosus group","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","Viridans group streptococci","30 mcg","27","27",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","Viridans group streptococci","30 mcg","26","26",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"1","1",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Delafloxacin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dalbavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oritavancin, S. anginosus group","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","Viridans group streptococci","30 mcg","16","16",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci",NA,"2","2",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","Viridans group streptococci","5 mcg","15","15",FALSE,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","Viridans group streptococci","15 mcg","IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","Viridans group streptococci","2 mcg","19","19",FALSE,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","Viridans group streptococci","20 mcg","17","17",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tedizolid, S. anginosus group","Viridans group streptococci","2 mcg","18","18",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Daptomycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Daptomycin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin","Viridans group streptococci",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin","Viridans group streptococci",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","Haemophilus influenzae","1 unit","12","12",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","Haemophilus influenzae","2 mcg","18","18",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[5/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv. | [4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. Isolates resistant to ampicillin can be reported resistant to amoxicillin oral.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","Haemophilus influenzae","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae",NA,"0.001","2",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","Haemophilus influenzae","2/1 mcg","50","15",FALSE,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","Haemophilus influenzae","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","Haemophilus influenzae","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","Haemophilus influenzae","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","Haemophilus influenzae","10 mcg","26","26",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","Haemophilus influenzae","30/10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","Haemophilus influenzae","30 mcg","32","32",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae",NA,"1","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","Haemophilus influenzae","30 mcg","27","25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","Haemophilus influenzae","30 mcg","50","27",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","Haemophilus influenzae","10 mcg","23","23",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","Haemophilus influenzae","10 mcg","20","20",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","Haemophilus influenzae","5 mcg","32","32",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","Haemophilus influenzae","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","Haemophilus influenzae","30 mcg","23","23",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","Haemophilus influenzae","5 mcg","30","30",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline","Haemophilus influenzae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","Haemophilus influenzae","30 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","Haemophilus influenzae","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae",NA,"2","2",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","Haemophilus influenzae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin","Haemophilus influenzae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","Haemophilus influenzae","5 mcg","18","18",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","Haemophilus influenzae","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"H.influenzae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","Moraxella catarrhalis","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis",NA,"4","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","Moraxella catarrhalis","30 mcg","20","20",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","Moraxella catarrhalis","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","Moraxella catarrhalis","5 mcg","20","17",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis",NA,"IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","Moraxella catarrhalis","10 mcg","IP","IP",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis",NA,"1","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","Moraxella catarrhalis","30 mcg","24","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis",NA,"4","8",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","Moraxella catarrhalis","30 mcg","21","18",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis",NA,"0.001","4",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","Moraxella catarrhalis","30 mcg","50","21",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","Moraxella catarrhalis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","Moraxella catarrhalis","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","Moraxella catarrhalis","10 mcg","33","33",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","Moraxella catarrhalis","5 mcg","31","31",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","Moraxella catarrhalis","5 mcg","29","29",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","Moraxella catarrhalis","5 mcg","26","26",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","Moraxella catarrhalis","30 mcg","23","23",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","Moraxella catarrhalis","5 mcg","28","28",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","Moraxella catarrhalis","15 mcg","23","23",FALSE,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","Moraxella catarrhalis","30 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","Moraxella catarrhalis","30 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","Moraxella catarrhalis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin","Moraxella catarrhalis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis",NA,"1","1",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","Moraxella catarrhalis","1.25/23.75 mcg","15","15",FALSE,FALSE,FALSE,NA,"M.catarrhalis"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)","Neisseria gonorrhoeae",NA,"0.06","1",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone","Neisseria gonorrhoeae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin","Neisseria gonorrhoeae",NA,"0.03","0.06",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin","Neisseria gonorrhoeae",NA,"0.125","0.25",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin","Neisseria gonorrhoeae",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline","Neisseria gonorrhoeae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin","Neisseria gonorrhoeae",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin","Neisseria gonorrhoeae",NA,"64","64",FALSE,FALSE,FALSE,NA,"N.gonorrhoeae"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)","Neisseria meningitidis",NA,"0.125","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)","Neisseria meningitidis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam","Neisseria meningitidis",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)","Neisseria meningitidis",NA,"0.016","0.016",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)","Neisseria meningitidis",NA,"1","1",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline","Neisseria meningitidis",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)","Neisseria meningitidis",NA,"2","2",FALSE,FALSE,FALSE,NA,"N.meningitidis"
NA,NA,"human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)","Neisseria meningitidis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"N.meningitidis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","Bacteroides spp.","10/10 mcg","25","25",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","Bacteroides spp.","2/1 mcg","14","14",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.",NA,"2","2",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","Bacteroides spp.","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.",NA,"2","2",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","Bacteroides spp.","10 mcg","23","23",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","Bacteroides spp.","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","Bacteroides spp.","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.",NA,"4","4",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","Bacteroides spp.","2 mcg","10","10",FALSE,FALSE,TRUE,"[5/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.",NA,"4","4",FALSE,FALSE,FALSE,"[6/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","Bacteroides spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[6/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","Prevotella spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","Prevotella spp.","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","Prevotella spp.","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","Prevotella spp.","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","Prevotella spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","Prevotella spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","Prevotella spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","Prevotella spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","Prevotella spp.","2 mcg","31","31",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.",NA,"4","4",FALSE,FALSE,FALSE,"[3/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","Prevotella spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[3/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin","Fusobacterium necrophorum and Fusobacterium nucleatum","1 unit","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin","Fusobacterium necrophorum and Fusobacterium nucleatum","2 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam","Fusobacterium necrophorum and Fusobacterium nucleatum","10/10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin-clavulanic acid, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. necrophorum","Fusobacterium necrophorum and Fusobacterium nucleatum","30/6 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Piperacillin-tazobactam, F. nucleatum","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem","Fusobacterium necrophorum and Fusobacterium nucleatum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem","Fusobacterium necrophorum and Fusobacterium nucleatum","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem","Fusobacterium necrophorum and Fusobacterium nucleatum","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin","Fusobacterium necrophorum and Fusobacterium nucleatum","2 mcg","30","30",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole","Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"1","1",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole","Fusobacterium necrophorum and Fusobacterium nucleatum","5 mcg","30","30",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","Clostridium perfringens","1 unit","15","15",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","Clostridium perfringens","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","Clostridium perfringens","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin","Clostridium perfringens",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","Clostridium perfringens","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","Clostridium perfringens","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","Clostridium perfringens","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","Clostridium perfringens","10 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","Clostridium perfringens","5 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","Clostridium perfringens","2 mcg","19","19",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens",NA,"4","4",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","Clostridium perfringens","5 mcg","16","16",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin","Clostridium innocuum",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin","Clostridium innocuum","2 mcg","21","21",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam","Clostridium innocuum",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam","Clostridium innocuum","10/10 mcg","28","28",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin","Clostridium innocuum",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin","Clostridium innocuum",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid","Clostridium innocuum",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid","Clostridium innocuum","2/1 mcg","19","19",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam","Clostridium innocuum",NA,"4","4",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam","Clostridium innocuum","30/6 mcg","24","24",FALSE,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Meropenem","Clostridium innocuum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Meropenem","Clostridium innocuum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Clindamycin","Clostridium innocuum",NA,"2","2",FALSE,FALSE,TRUE,"[4/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Clindamycin","Clostridium innocuum","2 mcg","17","17",FALSE,FALSE,TRUE,"[4/B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Metronidazole","Clostridium innocuum",NA,"4","4",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Metronidazole","Clostridium innocuum","5 mcg","19","19",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Benzylpenicillin","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Benzylpenicillin","Clostridium ramosum","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin","Clostridium ramosum","2 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam","Clostridium ramosum","10/10 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin","Clostridium ramosum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid","Clostridium ramosum",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid","Clostridium ramosum","2/1 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam","Clostridium ramosum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam","Clostridium ramosum","30/6 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ertapenem","Clostridium ramosum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ertapenem","Clostridium ramosum",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Imipenem","Clostridium ramosum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Imipenem","Clostridium ramosum","10 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Meropenem","Clostridium ramosum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Meropenem","Clostridium ramosum","10 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Metronidazole","Clostridium ramosum",NA,"4","4",FALSE,FALSE,FALSE,"[5/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Metronidazole","Clostridium ramosum","5 mcg","21","21",FALSE,FALSE,FALSE,"[5/C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Benzylpenicillin","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Benzylpenicillin","Clostridium septicum","1 unit","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin","Clostridium septicum","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam","Clostridium septicum","10/10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin","Clostridium septicum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid","Clostridium septicum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid","Clostridium septicum","2/1 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam","Clostridium septicum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam","Clostridium septicum","30/6 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ertapenem","Clostridium septicum",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ertapenem","Clostridium septicum","10 mcg","26","26",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Imipenem","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Imipenem","Clostridium septicum","10 mcg","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Meropenem","Clostridium septicum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Meropenem","Clostridium septicum","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Vancomycin","Clostridium septicum",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Vancomycin","Clostridium septicum","5 mcg","14","14",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Clindamycin","Clostridium septicum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Clindamycin","Clostridium septicum","2 mcg","24","24",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Metronidazole","Clostridium septicum",NA,"4","4",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Metronidazole","Clostridium septicum","5 mcg","21","21",FALSE,FALSE,FALSE,"[5/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin","Clostridium tertium","2 mcg","12","12",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam","Clostridium tertium","10/10 mcg","22","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin","Clostridium tertium",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin","Clostridium tertium",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid","Clostridium tertium",NA,"2","2",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid","Clostridium tertium","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ertapenem","Clostridium tertium",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ertapenem","Clostridium tertium",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Imipenem","Clostridium tertium",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Imipenem","Clostridium tertium","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Meropenem","Clostridium tertium",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Meropenem","Clostridium tertium","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Vancomycin","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Vancomycin","Clostridium tertium","5 mcg","13","13",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Metronidazole","Clostridium tertium",NA,"4","4",FALSE,FALSE,FALSE,"[3/B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Metronidazole","Clostridium tertium","5 mcg","20","20",FALSE,FALSE,FALSE,"[3/B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","Cutibacterium acnes","1 unit","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","Cutibacterium acnes","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","Cutibacterium acnes","10/10 mcg","33A","33",FALSE,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","Cutibacterium acnes","2/1 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","Cutibacterium acnes","30/6 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","Cutibacterium acnes","5 mcg","26","26",FALSE,FALSE,FALSE,"[3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","Cutibacterium acnes","30 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","Cutibacterium acnes","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","Cutibacterium acnes","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","Cutibacterium acnes","5 mcg","22","22",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","Cutibacterium acnes","2 mcg","26","26",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","Cutibacterium acnes","10 mcg","34","34",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Benzylpenicillin","Cutibacterium avidum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Benzylpenicillin","Cutibacterium avidum","1 unit","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin","Cutibacterium avidum","2 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam","Cutibacterium avidum","10/10 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin","Cutibacterium avidum",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid","Cutibacterium avidum","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam","Cutibacterium avidum",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam","Cutibacterium avidum","30/6 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Cefotaxime","Cutibacterium avidum",NA,"Note","Note",FALSE,FALSE,FALSE,"[5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Cefotaxime","Cutibacterium avidum","5 mcg","24","24",FALSE,FALSE,FALSE,"[5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ceftriaxone","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ceftriaxone","Cutibacterium avidum","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5/C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ertapenem","Cutibacterium avidum",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ertapenem","Cutibacterium avidum","10 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Imipenem","Cutibacterium avidum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Imipenem","Cutibacterium avidum","10 mcg","39","39",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Meropenem","Cutibacterium avidum",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Meropenem","Cutibacterium avidum","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Vancomycin","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Vancomycin","Cutibacterium avidum","5 mcg","19","19",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Clindamycin","Cutibacterium avidum",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Clindamycin","Cutibacterium avidum","2 mcg","33","33",FALSE,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Linezolid","Cutibacterium avidum",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Linezolid","Cutibacterium avidum","10 mcg","28","28",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Benzylpenicillin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Benzylpenicillin","Finegoldia spp.","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin","Finegoldia spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam","Finegoldia spp.","10/10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin","Finegoldia spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid","Finegoldia spp.","2/1 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam","Finegoldia spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam","Finegoldia spp.","30/6 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ertapenem","Finegoldia spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ertapenem","Finegoldia spp.","10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Imipenem","Finegoldia spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Imipenem","Finegoldia spp.","10 mcg","34","34",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Meropenem","Finegoldia spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Meropenem","Finegoldia spp.","10 mcg","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Vancomycin","Finegoldia spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Vancomycin","Finegoldia spp.","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Clindamycin","Finegoldia spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Clindamycin","Finegoldia spp.","2 mcg","23","23",FALSE,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Metronidazole","Finegoldia spp.",NA,"2","2",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Metronidazole","Finegoldia spp.","5 mcg","25","25",FALSE,FALSE,FALSE,"[6/D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Benzylpenicillin","Parvimonas micra",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Benzylpenicillin","Parvimonas micra","1 unit","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin","Parvimonas micra",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin","Parvimonas micra","2 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam","Parvimonas micra","10/10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin","Parvimonas micra",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid","Parvimonas micra","2/1 mcg","28","28",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam","Parvimonas micra",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam","Parvimonas micra","30/6 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ertapenem","Parvimonas micra",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ertapenem","Parvimonas micra","10 mcg","33","33",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Imipenem","Parvimonas micra",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Imipenem","Parvimonas micra","10 mcg","40","40",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Meropenem","Parvimonas micra",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Meropenem","Parvimonas micra","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Vancomycin","Parvimonas micra",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Vancomycin","Parvimonas micra","5 mcg","19","19",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Clindamycin","Parvimonas micra",NA,"1","1",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Clindamycin","Parvimonas micra","2 mcg","18","18",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Metronidazole","Parvimonas micra",NA,"1","1",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Metronidazole","Parvimonas micra","5 mcg","28","28",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin","Peptostreptococcus anaerobius",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin","Peptostreptococcus anaerobius","1 unit","20","20",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin","Peptostreptococcus anaerobius","2 mcg","25","25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam","Peptostreptococcus anaerobius","10/10 mcg","31","31",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin","Peptostreptococcus anaerobius",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid","Peptostreptococcus anaerobius","2/1 mcg","22","22",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam","Peptostreptococcus anaerobius","30/6 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem","Peptostreptococcus anaerobius",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem","Peptostreptococcus anaerobius","10 mcg","27","27",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Imipenem","Peptostreptococcus anaerobius",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Imipenem","Peptostreptococcus anaerobius","10 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Meropenem","Peptostreptococcus anaerobius",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Meropenem","Peptostreptococcus anaerobius","10 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin","Peptostreptococcus anaerobius",NA,"2","2",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin","Peptostreptococcus anaerobius","5 mcg","15","15",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin","Peptostreptococcus anaerobius",NA,"1","1",FALSE,FALSE,TRUE,"[6/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin","Peptostreptococcus anaerobius","2 mcg","17","17",FALSE,FALSE,TRUE,"[6/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole","Peptostreptococcus anaerobius",NA,"2","2",FALSE,FALSE,FALSE,"[7/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole","Peptostreptococcus anaerobius","5 mcg","22","22",FALSE,FALSE,FALSE,"[7/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin","Peptoniphilus spp.","1 unit","18","18",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin","Peptoniphilus spp.","2 mcg","21","21",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam","Peptoniphilus spp.","10/10 mcg","29","29",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid","Peptoniphilus spp.","2/1 mcg","23","23",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam","Peptoniphilus spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam","Peptoniphilus spp.","30/6 mcg","36","36",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ertapenem","Peptoniphilus spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ertapenem","Peptoniphilus spp.","10 mcg","32","32",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Imipenem","Peptoniphilus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Imipenem","Peptoniphilus spp.","10 mcg","37","37",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Meropenem","Peptoniphilus spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Meropenem","Peptoniphilus spp.","10 mcg","35","35",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Vancomycin","Peptoniphilus spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Vancomycin","Peptoniphilus spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Clindamycin","Peptoniphilus spp.",NA,"2","2",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Clindamycin","Peptoniphilus spp.","2 mcg","15","15",FALSE,FALSE,TRUE,"[4/C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Metronidazole","Peptoniphilus spp.",NA,"4","4",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Metronidazole","Peptoniphilus spp.","5 mcg","19","19",FALSE,FALSE,FALSE,"[5/E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"2","2",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole","Clostridioides difficile",NA,"IP","IP",FALSE,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral","Helicobacter pylori",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin","Helicobacter pylori",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole","Helicobacter pylori",NA,"8","8",FALSE,FALSE,FALSE,NA,"H.pylori"
NA,NA,"human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin","Helicobacter pylori",NA,"1","1",FALSE,FALSE,FALSE,NA,"H.pylori"
"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","Listeria monocytogenes","1 unit","13","13",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","Listeria monocytogenes","2 mcg","16","16",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","Listeria monocytogenes","10 mcg","26","26",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)","Listeria monocytogenes",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes",NA,"1","1",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","Listeria monocytogenes","15 mcg","25","25",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","Listeria monocytogenes","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,NA,"L.monocytogenes"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","Pasteurella spp.","1 unit","17","17",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","Pasteurella spp.","2/1 mcg","15","15",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","Pasteurella spp.","5 mcg","26","26",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","Pasteurella spp.","5 mcg","27","27",FALSE,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","Pasteurella spp.","30 mcg","23","23",FALSE,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline","Pasteurella spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","Pasteurella spp.","30 mcg","24","24",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2026","16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2026","16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","Pasteurella spp.","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"Pasteurella"
"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","Campylobacter jejuni and C. coli","5 mcg","50","26",FALSE,FALSE,FALSE,NA,"C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli",NA,"4","4",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. jejuni","Campylobacter jejuni and C. coli","15 mcg","20","20",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli",NA,"8","8",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Erythromycin,C. coli","Campylobacter jejuni and C. coli","15 mcg","18","18",FALSE,FALSE,FALSE,"[1/A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline","Campylobacter jejuni and C. coli",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli",NA,"2","2",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","Campylobacter jejuni and C. coli","30 mcg","30","30",FALSE,FALSE,FALSE,"[1/A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","50","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","17","17",FALSE,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","2 mcg","20","20",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium spp.other than C. diphtheriae and C. ulcerans","5 mcg","30","30",FALSE,FALSE,FALSE,NA,"Corynebacterium"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","Corynebacterium diphtheriae and C. ulcerans","1 unit","50","12",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","2",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","15",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","Corynebacterium diphtheriae and C. ulcerans","10 mcg","24","24",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","Corynebacterium diphtheriae and C. ulcerans","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Clindamycin, C. diphtheriae","Corynebacterium diphtheriae and C. ulcerans","2 mcg","15","15",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline","Corynebacterium diphtheriae and C. ulcerans",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans",NA,"1","1",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","Corynebacterium diphtheriae and C. ulcerans","30 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans",NA,"2","2",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","Corynebacterium diphtheriae and C. ulcerans","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","Corynebacterium diphtheriae and C. ulcerans","5 mcg","24","24",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","Corynebacterium diphtheriae and C. ulcerans","1.25/23.75 mcg","23","23",FALSE,FALSE,FALSE,NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","Aerococcus sanguinicola and A. urinae","1 unit","21","21",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","Aerococcus sanguinicola and A. urinae","2 mcg","26","26",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","Aerococcus sanguinicola and A. urinae","10 mcg","31","31",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","5 mcg","21","21",FALSE,FALSE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"2","2",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","Aerococcus sanguinicola and A. urinae","10 mcg","17","17",FALSE,FALSE,FALSE,"[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae",NA,"1","1",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","Aerococcus sanguinicola and A. urinae","5 mcg","16","16",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae",NA,"16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","Aerococcus sanguinicola and A. urinae","100 mcg","16","16",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","Aerococcus sanguinicola and A. urinae","5 mcg","25","25",FALSE,FALSE,FALSE,NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","Kingella kingae","1 unit","25","25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","Kingella kingae","2/1 mcg","22","22",FALSE,FALSE,FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","Kingella kingae","5 mcg","27","27",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","Kingella kingae","30 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","Kingella kingae","30 mcg","29","29",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae",NA,"0.03","0.03",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","Kingella kingae","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","Kingella kingae","5 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","Kingella kingae","15 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline","Kingella kingae",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","Kingella kingae","30 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","Kingella kingae","5 mcg","20","20",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","Kingella kingae","1.25/23.75 mcg","28","28",FALSE,FALSE,FALSE,NA,"K.kingae"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","Aeromonas spp.","30 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","Aeromonas spp.","10 mcg","24","21",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.",NA,"1","4",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","Aeromonas spp.","30 mcg","29","26",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.",NA,"0.25","0.5",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.",NA,"0.5","1",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","Aeromonas spp.","5 mcg","27","24",FALSE,FALSE,FALSE,NA,"Aeromonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.",NA,"1","1",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2026","16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","Aeromonas spp.","1.25/23.75 mcg","16","16",FALSE,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below).","Aeromonas"
"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans",NA,"4","4",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","Achromobacter xylosoxidans","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans",NA,"Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","A.xylosoxidans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","Achromobacter xylosoxidans","30 mcg","Note","Note",FALSE,FALSE,FALSE,"[2/A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent.","A.xylosoxidans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans",NA,"1","4",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","Achromobacter xylosoxidans","10 mcg","26","20",FALSE,FALSE,FALSE,NA,"A.xylosoxidans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2026","16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","Achromobacter xylosoxidans","1.25/23.75 mcg","26","26",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","A.xylosoxidans"
"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","Vibrio spp.","30/6 mcg","26","26",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","Vibrio spp.","5 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime, V. fluvialis","Vibrio spp.",NA,"IE","IE",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.",NA,"1","1",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","Vibrio spp.","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","Vibrio spp.","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","Vibrio spp.","5 mcg","23","23",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","Vibrio spp.","5 mcg","22","22",FALSE,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.",NA,"4","4",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","Vibrio spp.","15 mcg","16","16",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","Vibrio spp.","15 mcg","12","12",FALSE,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"0.5","0.5",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline","Vibrio spp.",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","Vibrio spp.","30 mcg","20","20",FALSE,FALSE,FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2026","16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2026","16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","Vibrio spp.","1.25/23.75 mcg","21","21",FALSE,FALSE,FALSE,NA,"Vibrio"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Imipenem","Bacillus spp.
except B. anthracis","10 mcg","30","30",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Meropenem","Bacillus spp.
except B. anthracis","10 mcg","25","25",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Ciprofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis",NA,"0.001","1",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Levofloxacin","Bacillus spp.
except B. anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Norfloxacin (screen only)","Bacillus spp.
except B. anthracis","10 mcg","21","21",FALSE,FALSE,FALSE,"[B]  | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Vancomycin","Bacillus spp.
except B. anthracis","5 mcg","10","10",FALSE,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Erythromycin","Bacillus spp.
except B. anthracis","15 mcg","24","24",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Clindamycin","Bacillus spp.
except B. anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus spp.
except B. anthracis",NA,"Linezolid","Bacillus spp.
except B. anthracis","10 mcg","22","22",FALSE,FALSE,FALSE,NA,"Bacillus"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","Bacillus anthracis","1 unit","50","18",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis",NA,"0.001","0.25",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","Bacillus anthracis","5 mcg","50","24",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis",NA,"0.001","0.5",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","Bacillus anthracis","5 mcg","50","23",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis",NA,"4","4",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","Bacillus anthracis","5 mcg","10","10",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","Bacillus anthracis","2 mcg","17","17",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"0.06","0.06",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline","Bacillus anthracis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis",NA,"0.125","0.125",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","Bacillus anthracis","30 mcg","26","26",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","Bacillus anthracis","10 mcg","20","20",FALSE,FALSE,FALSE,NA,"B.anthracis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2026","16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","Bacillus anthracis","5 mcg","12","12",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","Brucella melitensis","30 mcg","30","30",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","Brucella melitensis","5 mcg","50","27",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis",NA,"0.001","1",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","Brucella melitensis","5 mcg","50","28",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","Brucella melitensis","10 mcg","23","23",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis",NA,"1","1",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","Brucella melitensis","10 mcg","15","15",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"0.25","0.25",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline","Brucella melitensis",NA,"Note","Note",FALSE,FALSE,FALSE,"[1/A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis",NA,"0.5","0.5",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","Brucella melitensis","30 mcg","42","42",FALSE,FALSE,FALSE,NA,"B.melitensis "
"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis",NA,"2","2",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis "
"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","Brucella melitensis","5 mcg","20","20",FALSE,FALSE,TRUE,"[1/A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis "
"EUCAST 2026","16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis",NA,"0.125","0.125",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis "
"EUCAST 2026","16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","Brucella melitensis","1.25/23.75 mcg","29","29",FALSE,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone.","B.melitensis "
"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","Burkholderia pseudomallei","20/10 mcg","50","22",FALSE,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","Burkholderia pseudomallei","10 mcg","50","18",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","Burkholderia pseudomallei","10 mcg","29","29",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei",NA,"2","2",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","Burkholderia pseudomallei","10 mcg","24","24",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"0.001","2",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline","Burkholderia pseudomallei",NA,"Note","Note",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","Burkholderia pseudomallei","30 mcg","23","23",FALSE,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei",NA,"0.001","8",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","Burkholderia pseudomallei","30 mcg","50","22",FALSE,FALSE,FALSE,NA,"B.pseudomallei"
"EUCAST 2026","16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei",NA,"0.001","4",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2026","16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","Burkholderia pseudomallei","1.25/23.75 mcg","50","17",FALSE,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter.","B.pseudomallei"
"EUCAST 2026","16.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Bedaquiline","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.25","0.25",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2026","16.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Delamanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"0.06","0.06",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2026","16.1","human","human","MIC",NA,"The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Pretomanid","The Mycobacterium tuberculosis complex includes different species and variants such asM. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis.",NA,"Note","Note",FALSE,FALSE,FALSE,NA,"M.tuberculosis"
"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","Topical agents","10 mcg","16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","Topical agents","5 mcg","24","24",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","Topical agents","30 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","Topical agents","10 mcg","15","15",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","Topical agents","5 mcg","26","26",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","Topical agents","5 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","Topical agents","5 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","Topical agents","5 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","Topical agents","10 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","17","17",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol","Topical agents",NA,"16","16",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","Topical agents","30 mcg","18","18",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","Topical agents","10 mcg","23","23",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","Topical agents","10 mcg","14","14",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin","Topical agents",NA,"1","1",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","Topical agents","200 mcg","30","30",FALSE,FALSE,TRUE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","10","10",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","Topical agents","10 mcg","12","12",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","Topical agents","30 mcg","21","21",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","Topical agents",NA,"32","32",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","Topical agents",NA,"0.5","0.5",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin","Topical agents",NA,"4","4",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin","Topical agents",NA,"8","8",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"0.06","0.06",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","Topical agents","30 mcg","28","28",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","Topical agents","30 mcg","23","23",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents",NA,"0.125","0.125",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","Topical agents","5 mcg","Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"0.25","0.25",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","Topical agents",NA,"Note","Note",FALSE,FALSE,TRUE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents",NA,"2","2",FALSE,FALSE,TRUE,NA,"Topical agents"
"EUCAST 2026","16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","Topical agents","30 mcg","31","31",FALSE,FALSE,TRUE,NA,"Topical agents"